Amyloid-beta peptide (1-15) (Aβ1-15)

The Amyloid-beta N-terminal Aβ1–15 epitope is a specific sequence of the amyloid-beta peptide that serves as a primary target for Alzheimer's disease immunotherapy [1]. This 15-amino acid fragment is recognized as the immunodominant B-cell epitope of the full-length Aβ42 peptide, making it ideal for generating targeted antibodies [2]. Crucially, the Aβ1-15 region lacks the T-cell epitopes found in the mid-to-C-terminal regions of the peptide, which were associated with severe meningoencephalitis in early clinical trials [1, 2]. Monoclonal antibodies such as Aducanumab and Lecanemab bind to this N-terminal region to facilitate the clearance of amyloid plaques and neutralize toxic soluble oligomers [3, 4]. Active vaccines like CAD106 and UB-311 utilize fragments within this range to stimulate a safe humoral immune response [5, 6]. By focusing on this epitope, therapeutic interventions aim to reduce brain amyloid burden and slow the progression of cognitive decline [4]. Monitoring for these therapies involves neuroimaging to detect Amyloid-Related Imaging Abnormalities (ARIA) and fluid biomarkers to track changes in amyloid and tau pathology [4]. Citations: [1] Monsonego et al. (2003) J Clin Invest; [2] Agadjanyan et al. (2005) J Immunol; [3] Sevigny et al. (2016) Nature; [4] van Dyck et al. (2023) NEJM; [5] Winblad et al. (2012) Lancet Neurol; [6] Wang et al. (2007) Vaccine.

Other names

Amyloid-beta N-terminal epitopeAβ1-15 fragmentB-cell epitope of Amyloid-betaAmyloid-beta 1-15

Passive immunotherapy via monoclonal antibodies targeting the N-terminal epitope to promote plaque clearance through microglial phagocytosis; Active immunotherapy via vaccines using the N-terminal fragment to induce endogenous antibody production without T-cell activation [2, 3, 5].